Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives $12.63 Consensus PT from Analysts

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have earned a consensus rating of “Buy” from the nine research firms that are currently covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $12.6250.

CATX has been the topic of several research reports. Piper Sandler initiated coverage on shares of Perspective Therapeutics in a report on Thursday, February 19th. They issued an “overweight” rating and a $16.00 price objective on the stock. BTIG Research reiterated a “buy” rating and issued a $14.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, March 17th. UBS Group upped their price objective on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. B. Riley Financial upped their price objective on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. Finally, Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, May 5th.

Perspective Therapeutics Stock Performance

Shares of CATX opened at $2.95 on Thursday. Perspective Therapeutics has a 1-year low of $1.96 and a 1-year high of $6.16. The company’s fifty day simple moving average is $3.98 and its 200 day simple moving average is $3.77.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.16 million. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. Equities analysts forecast that Perspective Therapeutics will post -1.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Perspective Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Commodore Capital LP acquired a new position in shares of Perspective Therapeutics in the first quarter valued at $26,424,000. Avidity Partners Management LP increased its holdings in shares of Perspective Therapeutics by 88.4% in the first quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after purchasing an additional 2,839,266 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Perspective Therapeutics by 5.0% in the third quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock valued at $11,792,000 after acquiring an additional 163,532 shares during the period. Affinity Asset Advisors LLC boosted its position in shares of Perspective Therapeutics by 954.9% in the first quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock valued at $13,196,000 after acquiring an additional 2,864,582 shares during the period. Finally, Spruce Street Capital LP bought a new stake in shares of Perspective Therapeutics in the first quarter valued at about $10,955,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.